Natixis Advisors LLC Lowers Stake in IQVIA Holdings Inc. (NYSE:IQV)

Natixis Advisors LLC reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 35.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 159,437 shares of the medical research company's stock after selling 85,699 shares during the period. Natixis Advisors LLC owned about 0.09% of IQVIA worth $31,331,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of IQV. Raymond James Financial Inc. purchased a new stake in shares of IQVIA during the 4th quarter worth $236,120,000. FMR LLC lifted its position in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in IQVIA in the third quarter valued at $147,683,000. JPMorgan Chase & Co. lifted its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQV traded down $2.82 on Thursday, hitting $184.13. 1,344,522 shares of the company were exchanged, compared to its average volume of 1,229,630. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The business's fifty day moving average is $195.71 and its 200 day moving average is $209.36. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.29. The firm has a market capitalization of $32.46 billion, a P/E ratio of 24.55, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IQV shares. Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Citigroup reduced their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 price objective on the stock. Finally, UBS Group dropped their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.